Cumberland Pharmaceuticals closes USD 100 million branded-drug sale to Apotex unit

Cumberland Pharmaceuticals Inc.
APTINYX INC.

Cumberland Pharmaceuticals Inc.

CPIX

0.00

APTINYX INC.

APTX

0.00
  • Apotex bought Cumberland Pharmaceuticals’ U.S. branded pharmaceuticals line for USD 100 million in cash, funded at closing.
  • The deal integrates the companies’ branded U.S. businesses, shifting Cumberland’s focus toward its rare-disease pipeline.
  • Cumberland retained its product candidates and its majority stake in Cumberland Emerging Technologies.
  • Resources will be directed to ifetroban development, with programs spanning Duchenne muscular dystrophy cardiomyopathy, systemic sclerosis, idiopathic pulmonary fibrosis.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cumberland Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CL95903) on July 01, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.